409. Journal Club: The ARREST-AF Trial with Drs. Prashanthan Sanders and Mehak Dhande

409. Journal Club: The ARREST-AF Trial with D...

Up next

439. Atrial Fibrillation: Anti-Arrhythmic Drugs in the Management of Atrial Arrhythmias with Dr. Andrew Epstein

CardioNerds (Dr. Colin Blumenthal, Dr. Kelly Arps, and Dr. Natalie Marrero) discuss anti-arrhythmic drugs in the management of atrial fibrillation and atrial flutter with electrophysiologist Dr. Andrew Epstein. We discuss two major classes of anti-arrhythmic drugs, class IC and c ...  Show more

438. Heart Failure: Perioperative Heart Transplant Management with Dr. Dave Kaczorowski and Dr. Jason Katz

In this episode, the CardioNerds (Dr. Natalie Tapaskar, Dr. Jenna Skowronski, and Dr. Shazli Khan) discuss the process of heart transplantation from the initial donor selection to the time a patient is discharged with Dr. Dave Kaczorowski and Dr. Jason Katz. We dissect a case whe ...  Show more

Recommended Episodes

PRAGUE-25 Trial: Catheter Ablation Versus Antiarrhythmic Drugs With Risk Factor Modification for Treatment of AF
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

<div class="OutlineElement Ltr SCXW209201394 BCX0">

<span class= "TextRun SCXW209201394 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class= "NormalTextRun SCXW209201394 BCX0">The PRAGUE-25</span> <span class="NormalTextRun ...

  Show more

Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

The DapaTAVI trial, conducted across 39 centers in Spain, is the first study to evaluate the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, specifically dapagliflozin, in patients with heart failure undergoing transcatheter aortic valve implantation (TAVI). The trial ...  Show more

Review of the Primary Angioplasty in Myocardial Infarction Study Group trial
Cardiology Trials

N Engl J Med 1993;328:673-679Background: Previous trials established that thrombolysis improves mortality in patients with acute myocardial infarction, as seen in the GISSI-1 and ISIS-2 trials. However, thrombolysis has limitations, including an increased risk of bleeding and the ...  Show more

Sep 12 2025 This Week in Cardiology
This Week in Cardiology

More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit ...  Show more